Rhythm Pharmaceuticals announces commercial launch of IMCIVREE in Germany

Rhythm Pharmaceuticals announced the commercial launch of IMCIVREE in Germany for the treatment of obesity and control of hunger associated with Bardet-Biedl syndrome. The German Federal Joint Committee ruled that IMCIVREE is eligible for reimbursement by Statutory Health Insurances for BBS. The G-BA unanimously voted to exclude IMCIVREE from its lifestyle exemption list for patients with BBS, as done previously for biallelic pro-opiomelanocortin, including proprotein convertase subtilisin/kexin type 1, deficiency or biallelic leptin receptor deficiency. With this launch, IMCIVREE is now available to patients in nine global markets, including the United States, for treatment of POMC, PCSK1, or LEPR deficiency obesity and/or BBS. In 2022, Rhythm was granted marketing authorization for IMCIVREE by the EC for BBS and early-access authorization for setmelanotide in France. Rhythm expects to launch IMCIVREE for the treatment of patients with BBS in the Netherlands later this year and in Italy, Spain, and the UK in 2024.